Literature DB >> 15630698

Human serum albumin complexes with chlorophyll and chlorophyllin.

A Ahmed Ouameur1, R Marty, H A Tajmir-Riahi.   

Abstract

Porphyrins and their metal derivatives are strong protein binders. Some of these compounds have been used for radiation sensitization therapy of cancer and are targeted to interact with cellular DNA and protein. The presence of several high-affinity binding sites on human serum albumin (HSA) makes it possible target for many organic and inorganic molecules. Chlorophyll a and chlorophyllin (a food-grade derivative of chlorophyll), the ubiquitous green plant pigment widely consumed by humans, are potent inhibitors of experimental carcinogenesis and interact with protein and DNA in many ways. This study was designed to examine the interaction of HSA with chlorophyll (Chl) and chlorophyllin (Chln) in aqueous solution at physiological conditions. Fourier transform infrared, UV-visible, and CD spectroscopic methods were used to determine the pigment binding mode, the binding constant, and the effects of porphyrin complexation on protein secondary structure. Spectroscopic results showed that chlorophyll and chlorophyllin are located along the polypeptide chains with no specific interaction. Stronger protein association was observed for Chl than for Chln, with overall binding constants of K(Chl) = 2.9 x 10(4)M(-1) and K(Chln) = 7.0 x 10(3)M(-1). The protein conformation was altered (infrared data) with reduction of alpha-helix from 55% (free HSA) to 41-40% and increase of beta-structure from 22% (free HSA) to 29-35% in the pigment-protein complexes. Using the CDSSTR program (CD data) also showed major reduction of alpha-helix from 66% (free HSA) to 58 and 55% upon complexation with Chl and Chln, respectively.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15630698     DOI: 10.1002/bip.20173

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  8 in total

1.  Physicochemical and Antioxidant Properties of Riboflavin in Dextran70/HSA Systems.

Authors:  Mariana Voicescu; Sorana Ionescu; Cecilia Lete
Journal:  J Fluoresc       Date:  2018-06-26       Impact factor: 2.217

2.  E2F4 and ribonucleotide reductase mediate S-phase arrest in colon cancer cells treated with chlorophyllin.

Authors:  Korakod Chimploy; G Dario Díaz; Qingjie Li; Orianna Carter; Wan-Mohaiza Dashwood; Christopher K Mathews; David E Williams; George S Bailey; Roderick H Dashwood
Journal:  Int J Cancer       Date:  2009-11-01       Impact factor: 7.396

3.  Interactions of Isophorone Derivatives with DNA: Spectroscopic Studies.

Authors:  Marco Deiana; Katarzyna Matczyszyn; Julien Massin; Joanna Olesiak-Banska; Chantal Andraud; Marek Samoc
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

4.  Determination of LMF binding site on a HSA-PPIX complex in the presence of human holo transferrin from the viewpoint of drug loading on proteins.

Authors:  Zohreh Sattar; Mohammad Reza Saberi; Jamshidkhan Chamani
Journal:  PLoS One       Date:  2014-01-02       Impact factor: 3.240

5.  Binding Performance of Human Intravenous Immunoglobulin and 20(S)-7-Ethylcamptothecin.

Authors:  Yong-Chun Liu; Ying-Ying Li; Xiao-Jun Yao; Hui-Li Qi; Xiao-Xia Wei; Jian-Ning Liu
Journal:  Molecules       Date:  2018-09-18       Impact factor: 4.411

6.  Morphological analysis and interaction of chlorophyll and BSA.

Authors:  Filipe D S Gorza; Graciela C Pedro; Tarquin F Trescher; Romário J da Silva; Josmary R Silva; Nara C de Souza
Journal:  Biomed Res Int       Date:  2014-05-18       Impact factor: 3.411

7.  Clinical study of Shengxuening tablet combined with rHuEPO for the treatment of renal anemia of maintenance hemodialysis patients.

Authors:  Xin Cheng; Guojun Yu; Jiangping Hu; Xuefeng Xu; Fang Luo; Ping Shen; Guosheng Zhang; Ning Yang
Journal:  Exp Ther Med       Date:  2016-04-28       Impact factor: 2.447

8.  Characterization of chlorophyll binding to LIL3.

Authors:  Astrid Elisabeth Mork-Jansson; Lutz Andreas Eichacker
Journal:  PLoS One       Date:  2018-02-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.